AbbVie (NYSE: ABBV) reported strong Q4 2025 financials, with a 10% year-over-year revenue growth and adjusted earnings increasing by more than 25%. Despite a 26% decline in Humira sales, the drug still generated over $1 billion in quarterly revenue. Key products, Skyrizi and Rinvoq, saw respective increases of 30% and 18.3%, while segment performance in Neurology rose by 17.9%. The company provided a positive outlook for 2026, with adjusted EPS guidance of $14.37, surpassing analyst expectations.
Analysts project a price target of $250 for AbbVie, indicating a potential 25% upside, with some forecasts suggesting up to a 50% increase. Institutional investors own over 70% of the stock, demonstrating strong buying activity throughout 2025 and into early 2026, which adds market support. Overall, AbbVie aims for a 6% compound annual growth rate in dividends as it prepares for a 13th distribution increase post-spin-off, with risks largely mitigated by share buybacks.
